BioMimetic Therapeutics’ Augment bone graft
This article was originally published in The Gray Sheet
Executive Summary
Company files the first two of three modules of a premarket approval application with FDA for its Augment bone graft. The last module, containing clinical data, will be submitted in the fourth quarter, BioMimetic says. The firm recently reported it had closed enrollment of a 436-patient North American clinical trial comparing Augment to autograft for foot and ankle fusions (1"The Gray Sheet" Jan. 19, 2009)